• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Pharmaceuticals

Kaleo announces US availability, pricing of allergy auto-injector

January 20, 2017 By Sarah Faulkner

Kaleo announces US availability, pricing of allergy auto-injector

Kaléo Inc. said yesterday that its Auvi-Q epinephrine auto-injector will be available by prescription in the U.S. beginning Feb. 14th. The Richmond, Virginia-based company’s emergency allergy treatment was pulled from the market in 2015 due to manufacturing issues. The Epipen competitor device will be sold at a list price of $4,500, but Kaléo said that as a […]

Filed Under: Auto-injectors, Featured, Pharmaceuticals, Respiratory, Wall Street Beat Tagged With: Kaleo Inc, Mylan

Study finds financial ties between researchers, industry associated with positive trial results

January 19, 2017 By Sarah Faulkner

Study finds financial ties between researchers, industry associated with positive trial results

A study conducted by a team of U.S. researchers found that financial ties between researchers and the companies that make the drugs they are studying are independently associated with positive trial results. The team’s work was published in The BMJ this week. The study was observational, so the results can’t be used to draw concrete conclusions. But the […]

Filed Under: Clinical Trials, Pharmaceuticals, Policy, Research & Development, Wall Street Beat

Grifols pays $51m for minority stake in Access Biologicals

January 12, 2017 By Brad Perriello

biologics

Grifols (NSDQ:GRFS) said today that it paid $51 million for a 49% stake in Access Biologicals, in a deal that includes an option to acquire the rest of the business. That option, for the remaining 51% share in Vista, Calif.-based Access, goes live in 2022, Grifols said. The agreement also includes a provision to supply Access with non-human-use […]

Filed Under: Diagnostics, Mergers & Acquisitions, Pharmaceuticals, Wall Street Beat Tagged With: Access Biologicals, Grifols

FDA warns on MRI risks with infusion pumps

January 12, 2017 By Sarah Faulkner

FDA

The FDA issued a warning today that the strong magnetic fields used in an MRI exam can affect implantable infusion pumps. The federal watchdog has received reports of serious adverse events, including patient death, associated with using an infusion pump in an MR environment. The reports claim that some patients have experienced inaccurate medication dosing […]

Filed Under: Diagnostics, Featured, Food & Drug Administration (FDA), Hospital Care, Imaging, Pharmaceuticals

J&J to publish list of average drug price increases

January 10, 2017 By Sarah Faulkner

Johnson & Johnson

Johnson & Johnson (NYSE:JNJ) is reportedly issuing a report next month that will detail how much it has raised the list prices for its prescription drugs. The report will describe average increases in list prices and the average prices after discounts. The move comes after some pharmaceutical companies, including Allergan (NYSE:AGN) and Novo Nordisk (NYSE:NVO), have pledged […]

Filed Under: Featured, Pharmaceuticals, Policy, Wall Street Beat Tagged With: Allergan, johnsonandjohnson, Mylan, Novo Nordisk

scPharmaceuticals closes $46m Series B round

January 4, 2017 By Sarah Faulkner

scPharmaceuticals said today that it closed a $45.6 million Series B round, co-led by OrbiMed and a subsidiary of Sun Pharmaceutical Industries. Other investors included 5AM Ventures and Lundbeckfond Ventures. The investment will be used to support the development of the operational and commercial infrastructure needed to bring Furoscix and the sc2Wear Infusor to market […]

Filed Under: Drug-Device Combinations, Featured, Funding Roundup, Pharmaceuticals, Wall Street Beat Tagged With: scPharmaceuticals

Neurelis wins fast track designation from FDA for intranasal diazepam spray

January 4, 2017 By Sarah Faulkner

Neurelis closes Series B for intranasal diazepam spray

Neurelis, Inc. said today that it won fast track designation from the FDA for its intranasal diazepam spray. The  nasal formulation of diazepam, which is being developed for pediatric and adult epilepsy patients who experience repititive or cluster seizures, is in the final stage of clinical development, according to Neurelis. The company expects to submit […]

Filed Under: Featured, Food & Drug Administration (FDA), Neurological, Pharmaceuticals, Regulatory/Compliance, Wall Street Beat Tagged With: Neurelis Inc.

Braeburn Pharmaceuticals files plans for $150m IPO

January 3, 2017 By Sarah Faulkner

Braeburn Pharmaceuticals

Braeburn Pharmaceuticals filed plans for a $150 million initial public offering last week with the Securities & Exchange Commission, leaving out any specific pricing details. The Princeton, N.J.-based company plans to list its shares on the Nasdaq market under the symbol “BBRX”. JPMorgan, Merrill Lynch and Deustche Bank are underwriters for the offering and Apple […]

Filed Under: Drug-Device Combinations, Featured, Funding Roundup, Initial Public Offering (IPO), Pain Management, Pharmaceuticals, Wall Street Beat Tagged With: Braeburn Pharmaceuticals

IntelGenx, Endo Ventures ink development and commercialization deal

December 28, 2016 By Sarah Faulkner

IntelGenx

IntelGenx (OTCQX:IGXT) said today that it inked a development and commercialization deal with pharmaceutical company Endo Ventures. According to the agreement, the 2 companies will develop a new product using IntelGenx’s VersaFilm drug delivery technology to bring to the market in the U.S. Endo will have certain exclusive rights to market and sell the product in the […]

Filed Under: Featured, Pharmaceuticals, Research & Development, Wall Street Beat Tagged With: Endo Ventures Inc., IntelGenx

Sanofi sues Nordisk over Tresiba marketing claims in U.S.

December 28, 2016 By Sarah Faulkner

Sanofi sues Nordisk over Tresiba marketing claims in U.S.

Sanofi (NYSE:SNY) said yesterday that it is suing competitor Novo Nordisk (NYSE:NVO) for “misleading” marketing materials that claim Sanofi’s insulin drugs Lantus and Toujeo will be “blocked” by U.S. pharmacy benefit manager CVS Caremark in January and that patients should switch to Nordisk’s Tresiba. CVS is replacing both Sanofi’s and Nordisk’s drugs with Eli Lilly’s Basaglar on […]

Filed Under: Diabetes, Drug-Device Combinations, Featured, Legal News, Pharmaceuticals, Wall Street Beat Tagged With: Actelion Pharmaceuticals, johnsonandjohnson, Novo Nordisk, Sanofi-Aventis

  • « Go to Previous Page
  • Page 1
  • Interim pages omitted …
  • Page 195
  • Page 196
  • Page 197
  • Page 198
  • Page 199
  • Interim pages omitted …
  • Page 206
  • Go to Next Page »

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS